The Full Wiki

More info on Bapineuzumab

Bapineuzumab: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Bapineuzumab ?
Monoclonal antibody
Type whole antibody
Source humanized (from mouse)
Target beta-amyloid (Aβ)
Identifiers
CAS number 648895-38-9
ATC code none
Chemical data
Formula C6466H10018N1734O2026S44 
Mol. mass 148.8 kDa (major glycoform)
Therapeutic considerations
Pregnancy cat.  ?
Legal status

Bapineuzumab is a humanized monoclonal antibody that acts on the nervous system and has potential therapeutic value for the treatment of Alzheimer's disease and possibly glaucoma.[1]

Bapineuzumab is an antibody to the beta-amyloid (Aβ) plaques that are believed to underlie Alzheimer's disease neuropathology. In previous clinical trials for vaccination against human beta amyloid, called AN-1792, patients with Alzheimer's disease using active immunization had positive outcomes with removal of plaques, but 6% of subjects developed aseptic meningitis and the trial was stopped.[2]

Bapineuzumab is currently being co-developed by the pharmaceutical companies Élan and Wyeth and entered Phase III trials in December 2007.[3]

In patients receiving the highest dose, e.g. 2 mg, MRI scans showed an accumulation of water in brain tissue (vasogenic edema). No health risks were found in subjects receiving either 0.5 or 1 mg of bapineuzumab. Patients who have been receiving or have been scheduled to receive the highest dose will be either removed from the trials or switched to lower doses.[4]

References

  1. ^ Sample, Ian (2007-08-07). "New Alzheimer's drugs might help prevent glaucoma". The Guardian. http://www.guardian.co.uk/science/2007/aug/07/3. Retrieved 2008-06-18. 
  2. ^ Woodhouse, Adele; Dickson, Tracey C.; Vickers, James C. (2007). "Vaccination strategies for Alzheimer's disease: A new hope?". Drugs & Aging (Mairangi Bay, Auckland, New Zealand: Adis International) 24 (2): 107–119. doi:1170-229X/07/0002-0107/ (inactive 2010-01-06). PMID 17313199. "The vigour of international research on immunotherapy for AD provides significant hope for a strong therapeutic lead for the escalating number of individuals who will develop this otherwise incurable condition.". 
  3. ^ Elan Corporation (2008-06-17). "Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease". Press release. http://newsroom.elan.com/phoenix.zhtml?c=88326&p=irol-newsArticle&ID=1166655. Retrieved 2008-06-18. "Elan and Wyeth plan to continue all four studies in the previously disclosed bapineuzumab Phase 3 clinical program" 
  4. ^ Pogatchnik, Shawn (2009-04-02). "Drug Makers Stop Top Dosage in Alzheimer's Trial". Drug Discovery & Development. http://www.dddmag.com/news-Elan-Stops-Top-Dosage-In-Alzheimers-Trial-040209.aspx. Retrieved 2009-04-16. 
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message